BioMarin, Enzyme Replacement Therapy, Phase 3 Failure **FACT BLOCK:** BioMarin drug failed primary endpoint. No clinical benefit observed. Rare disease trial results negative. Major pipeline setback confirmed. BioMarin Pharmaceutical's enzyme replacement therapy, BMN 331, failed its Phase 3 ENVISION trial. The study targeted ENPP1 deficiency, a rare genetic disorder. The primary endpoint, a composite measure of disease progression, was not met. Specifically, the drug did not demonstrate a statistically significant improvement in clinical outcomes compared to placebo, indicating a lack of efficacy. This outcome impacts BMN 331's regulatory path. Under FDA and EMA guidelines, a failed primary endpoint in a pivotal Phase 3 study typically precludes marketing authorization. BioMarin will likely need to conduct further trials or re-evaluate the drug's mechanism. This aligns with 21 CFR 314.126, requiring substantial evidence of effectiveness for approval. No prior EMA action for BMN 331 is recorded in the BrunoSan database. The failure is a blow to BioMarin's rare disease portfolio and its acquisition strategy. Competitors like Ultragenyx and Sanofi, also active in rare genetic disorders, may see an advantage. This setback could shift investor focus towards BioMarin's existing commercial products. A strategic pipeline review is expected by Q3 2026.